We Are Kalypso Wellness Centers
Over 90% of patients in the advanced stage of cancer report the most devastating complication is uncontrolled pain. Kalypso is revolutionizing palliative care for cancer patients through low dose infusion ketamine treatments to provide comfort and quality of life at any stage of cancer.
Studies in recent years have demonstrated ketamine is used in palliative care settings as a co-analgesic for intractable cancer pain and for neuropathic pain which is unresponsive or poorly responsive to first-line analgesics.
Randomized, double-blind, placebo-controlled study, N = 187 Inclusion criteria: chronic cancer pain refractory to standard opioids and co-analgesics at predefined dose levels (pain score ≥3/10).
Primary outcome: clinically relevant improvement in pain at the end of the 5-day study period “Clinically relevant” = reduction in pain score by ≥2 points from baseline in the absence of more than 4 breakthrough doses of analgesia over prior 24 hrs.
Source: 2009 Dec 15;147(1-3):107-15